Provided by Tiger Trade Technology Pte. Ltd.

INVESCO PHARMACEUTICALS ETF

130.98
+0.95270.73%
Post-market: 132.061.08+0.82%16:20 EDT
Volume:8K
Turnover:1.10M
Market Cap:537.03M
PE:6.79
High:131.13
Open:130.41
Low:130.38
Close:130.03
52wk High:131.68
52wk Low:90.01
Shares:4.10M
Float Shares:4.10M
Volume Ratio:0.40
T/O Rate:0.20%
Dividend:1.06
Dividend Rate:0.81%
EPS(TTM):19.29
EPS(LYR):21.73
ROE:23.89%
ROA:0.60%
PB:1.61
PE(LYR):6.03

Loading ...

Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Alvotech (ALVO) and Abbott Laboratories (ABT)

TIPRANKS
·
Aug 21

Johnson & Johnson Says Multiple Myeloma Treatment Approved by European Commission

MT Newswires Live
·
Aug 21

Analysts Have Conflicting Sentiments on These Healthcare Companies: Abbott Laboratories (ABT) and Doximity (DOCS)

TIPRANKS
·
Aug 21

PRESS Digest-Wall Street Journal - August 21

Reuters
·
Aug 21

Abbott : TD Cowen Raises Target Price to $135 from $115

THOMSON REUTERS
·
Aug 21

Perrigo Co. PLC Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Aug 21

Does J&J’s MONARCH QUEST 3 Approval and MedTech Momentum Change The Bull Case For Johnson & Johnson (JNJ)?

Simply Wall St.
·
Aug 21

Abbott Reaches Agreements to Resolve Portion of Litigation over Infant Formula

Reuters
·
Aug 21

Abbott resolves portion of litigation regarding specialty infant formulas

TIPRANKS
·
Aug 21

Abbott Agrees to Settle Preterm Infant Formula NEC Lawsuits for About $670 Million

Reuters
·
Aug 21

Abbott Reaches Agreements to Resolve a Portion of Litigation Involving Its Specialty Formulas for Preterm Infants

THOMSON REUTERS
·
Aug 21

Abbott - to Pay About $670 Mln to Resolve Gill Case and Nec Claims

THOMSON REUTERS
·
Aug 21

Abbott - Reaches Agreements to Resolve Gill Case and 2,000 Related Claims

THOMSON REUTERS
·
Aug 21

Abbott - About 1,700 Lawsuits Remain Pending Involving Claims for 12,700 Infants

THOMSON REUTERS
·
Aug 21

Sector Update: Healthcare Stocks Fall Thursday Afternoon

MT Newswires Live
·
Aug 21

AbbVie Targets Next-Gen BOTOX Combo With New Glabellar Lines Study

TIPRANKS
·
Aug 21

Eli Lilly Advances Early-Stage Eloralintide Trial: What Investors Should Watch

TIPRANKS
·
Aug 21

Eli Lilly’s Lebrikizumab Trial Completion Signals New Growth Path in Atopic Dermatitis

TIPRANKS
·
Aug 21

Eli Lilly Revenue Jumps 48% as Mounjaro and Zepbound Sales Reach $14.9B

TradingKey
·
Aug 20

Pharma Sector Doubles Down on AI Amid Hopes of Slashing Costs, Timelines

Reuters
·
Aug 20